Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies
Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies
复制标题
DOI：
10.2217/14796694.4.3.341
复制
发表时间：
2008-06-01
期刊：
影响因子：
3.3
通讯作者：
Yang, Haining
中科院分区：
文献类型：
--
作者：
Kbeck, Amanda;Pass, Harvey I.;Yang, Haining
Ranpirnase 最初是从北方豹蛙 (Rana pipiens) 的卵母细胞中分离出来的，是胰腺 RNase A 核糖核酸酶超家族的成员。 Ranpirnase 在体外和体内发挥抗增殖和细胞毒性作用，并已被证明与不同的癌症治疗药物具有协同作用。 ranpirnase 的细胞毒性和细胞抑制作用是 tRNA 降解的结果，导致蛋白质翻译中断和诱导程序性细胞死亡（细胞凋亡）。 Ranpirnase 已被证明可以靶向人类癌细胞系和动物模型中的恶性细胞，并在临床研究中证明对治疗多种人类癌症有效。大多数临床研究都是在恶性间皮瘤患者中进行的，目前正在进行一项治疗这种疾病的验证性 IIIb 期试验。由于其对恶性细胞的选择性破坏和有利的毒理学，兰比纳斯是一种有前途的抗肿瘤剂，具有传统细胞毒性药物所缺乏的理想特性。
Ranpirnase, originally isolated from oocytes of the northern leopard frog (Rana pipiens), is a member of the pancreatic RNase A superfamily of ribonucleases. Ranpirnase exerts anti proliferative and cytotoxic effects in vitro and in vivo and has been shown to act synergistically with different cancer therapeutic agents. The cytotoxic and cytostatic effects of ranpirnase are the consequence of tRNA degradation that results in the disruption of protein translation and the induction of programmed cell death (apoptosis). Ranpirnase has been shown to target malignant cells both in human cancer cell lines and in animal models, and has demonstrated efficacy in the treatment of several human cancers in clinical studies. Most clinical studies have been conducted in patients with malignant mesothelioma, and a confirmatory Phase IIIb trial is currently underway for the treatment of this disease. Owing to its selective destruction of malignant cells and favorable toxicology ranpirnase is a promising antitumor agent with ideal attributes that are generally profile, lacking in conventional cytotoxic drugs.